2. Search Result
Search Result
Results for "

LILRB2

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

4

Inhibitory Antibodies

9

Recombinant Proteins

2

Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS07652
    LILRB2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    LILRB2 Human Pre-designed siRNA Set A contains three designed siRNAs for LILRB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LILRB2 Human Pre-designed siRNA Set A
    LILRB2 Human Pre-designed siRNA Set A
  • HY-P990061
    Polzastobart

    JTX 8064

    		 LILRB Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
    Polzastobart
  • HY-RS24023
    Lilrb2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Lilrb2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lilrb2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Lilrb2 Rat Pre-designed siRNA Set A
    Lilrb2 Rat Pre-designed siRNA Set A
  • HY-P991306
    ATG-032

    		LILRB Transmembrane Glycoprotein Cancer
    ATG-032 is a human monoclonal antibody (mAb) targeting LILRB2/ILT4. ATG-032 can be used in haematological malignancies research.
    ATG-032
  • HY-P992388
    IO-108

    		LILRB Cancer
    IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors [2].
    IO-108
  • HY-P992353
    ES009

    		LILRB Cancer
    ES009 is a high-affinity LILRB2 antagonist, with IC50 values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer [2] .
    ES009

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: